Skip to main content

Table 1 Experimental design of mouse vaccination and challenge

From: Potential of recombinant inorganic pyrophosphatase antigen as a new vaccine candidate against Baylisascaris schroederi in mice

Trial and experimental group

Number of mice

0, 2, 4 wpv b

6-wpv b

1-wpc c

1-11 wpc c(80-dpc)

  

Vaccination

Cytokine assay

Challenge

Larval recovery

Mortality

(Trial I)

 

(3 times per group)

(No. a)

(No. a, d)

(No. a)

(No. a)

rBsc-PYP-1/FCA/PBS

30

rBsc-PYP-1 (FCA plus PBS)

10

20

10

10

FCA/PBS

30

FCA plus PBS

10

20

10

10

PBS

30

PBS

10

20

10

10

Trial and experimental group

Number of mice

0, 2, 4 wpv b

5-wpv b

6-wpv b

1-wpc c

1-12 wpc c (80-dpc)

  

Vaccination

Challenge

Cytokine assay

Larval recovery

Mortality

(Trial II)

 

(3 times per group)

(No. a )

(No. a, e )

(No. a, f )

(No. a )

rBsc-PYP-1/FCA/PBS

30

rBsc-PYP-1 (FCA plus PBS)

20

10

10

-

FCA/PBS

30

FCA plus PBS

20

10

10

-

PBS

30

PBS

20

10

10

-

  1. a Number of mice involved in this assay.
  2. b Week(s) post-vaccination.
  3. c Week(s) post-challenge.
  4. d Number of remaining mice in each experimental group after “Cytokine assay” and used for the subsequent determinations of “Larval recovery” and “Mortality”.
  5. e Number of remaining mice in each experimental group after “Challenge”.
  6. f Number of mice derived from “Challenge”.